What is a clinical trial?

A clinical trial is a research study involving human participants designed to evaluate medical interventions — such as drugs, devices, or behavioral strategies. Trials follow a structured protocol and are registered on ClinicalTrials.gov. They progress through phases: Phase 1 (safety), Phase 2 (efficacy), Phase 3 (large-scale comparison), and Phase 4 (post-market surveillance).

How do I find clinical trials I'm eligible for?

You can search ClinicalTrials.gov or use ClinicalMetric to filter by condition, phase, or location. Each trial listing includes eligibility criteria such as age range, sex, diagnosis, and prior treatment history. Contact the study team directly or ask your physician to refer you to a relevant trial.

Are clinical trials safe to participate in?

Clinical trials are conducted under strict ethical and regulatory oversight, including IRB approval and FDA regulation in the US. All participants must give informed consent after reviewing potential risks and benefits. Phase 1 trials carry more uncertainty, while Phase 3 trials involve interventions with an established safety profile. Participation is always voluntary and you may withdraw at any time.

What are the phases of clinical trials?

Clinical trials progress through four main phases. Phase 1 tests safety and dosing in a small group (20–80 people). Phase 2 evaluates efficacy and side effects in a larger group (100–300). Phase 3 compares the intervention against standard treatments in thousands of participants. Phase 4 occurs after approval and monitors long-term effects in the general population.

Do participants get paid for joining clinical trials?

Many clinical trials offer compensation for time and travel expenses, though payment structures vary widely by study. Compensation is not intended to be coercive. Some trials also cover treatment costs for participants. Always review the consent form carefully and ask the study coordinator about any financial considerations before enrolling.

Multiple Sclerosis Clinical Trials 2026: New DMTs, Remyelination & Progressive MS

Medical Notice

This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.

Summary

Multiple sclerosis research in 2026 is focused on two major unmet needs: treating progressive MS (primary and secondary progressive forms that respond poorly to current drugs) and repairing myelin damage already done. BTK inhibitors represent the most significant new drug class in MS since natalizumab, and remyelination agents are finally entering Phase 2/3 trials. For patients with relapsing MS, high-efficacy therapies are now being moved to earlier lines of treatment.

BTK Inhibitors: The New Frontier

Bruton's tyrosine kinase (BTK) inhibitors represent the most promising new class of MS drugs in over a decade. Unlike current disease-modifying therapies (DMTs) that primarily work in the bloodstream, BTK inhibitors penetrate the central nervous system and target both B cells and microglia — the brain's resident immune cells thought to drive progressive disease.

Four BTK inhibitors are in Phase 3 MS trials: tolebrutinib (Sanofi), fenebrutinib (Roche), evobrutinib (Merck), and orelabrutinib (InnoCare). The HERCULES and GEMINI trials for tolebrutinib are particularly closely watched — results are expected in 2026. These drugs are being tested in both relapsing and progressive MS, representing a potential breakthrough for patients who currently have limited options.

Remyelination: Repairing the Damage

Current DMTs reduce new lesion formation but don't repair existing myelin damage. Remyelination therapies aim to stimulate oligodendrocyte precursor cells to rebuild the myelin sheath. Several approaches are in trials:

PIPE-307 (Contineum Therapeutics): M1 muscarinic receptor antagonist — Phase 2 results showed remyelination signals on MRI
Opicinumab (Biogen): Anti-LINGO-1 antibody — completed Phase 2, effects in specific patient subgroups
Bazedoxifene: Repurposed SERM with remyelination activity in preclinical models, entering Phase 2

Stem Cell Trials for Progressive MS

Autologous hematopoietic stem cell transplantation (AHSCT) involves harvesting the patient's own stem cells, using high-dose chemotherapy to "reset" the immune system, then reinfusing the stem cells. Observational data and Phase 2 trials show significant benefit in highly active relapsing MS. The MIST trial (published 2019) showed AHSCT superior to disease-modifying therapy at 5 years in a Phase 3 comparison.

Mesenchymal stem cell (MSC) trials are also active — these cells have potential neuroprotective and anti-inflammatory effects without the toxicity of AHSCT. Phase 2 results are expected in 2026.

Finding MS Trials in 2026

The MS Society and National MS Society both maintain trial-matching tools. ClinicalTrials.gov searches for "multiple sclerosis" with status "Recruiting" return over 300 active studies. Key eligibility considerations: EDSS (disability) score, MS subtype (RRMS, SPMS, PPMS), current and prior DMT use, and time since last relapse. Many trials exclude patients who have received high-efficacy therapies (alemtuzumab, AHSCT) within the past few years.